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Abstract
The cause of Crohn’s disease (CD) has posed a conundrum for at least a
century. A large body of work coupled with recent technological advances in
genome research have at last started to provide some of the answers. Initially
this review seeks to explain and to differentiate between bowel inflammation in
the primary immunodeficiencies that generally lead to very early onset diffuse
bowel inflammation in humans and in animal models, and the real syndrome of
CD. In the latter, a trigger, almost certainly enteric infection by one of a
multitude of organisms, allows the faeces access to the tissues, at which stage
the response of individuals predisposed to CD is abnormal. Direct investigation
of patients’ inflammatory response together with genome-wide association
studies (GWAS) and DNA sequencing indicate that in CD the failure of acute
inflammation and the clearance of bacteria from the tissues, and from within
cells, is defective. The retained faecal products result in the characteristic
chronic granulomatous inflammation and adaptive immune response. In this
review I will examine the contemporary evidence that has led to this
understanding, and look for explanations for the recent dramatic increase in the
incidence of this disease.
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General introduction
The enigma that is the cause of Crohn’s disease (CD) has puzzled 
clinicians and scientists from time immemorial. It is generally 
accepted that CD results from an aberrant immune response to com-
mensal microflora in genetically susceptible individuals1, however, 
the nature of the immune defects, the responsible microflora and 
the genetic susceptibility remain incompletely defined and actively 
debated. With advances in genomic technologies our understanding 
of this puzzling condition is evolving, and answers forthcoming. 
The purpose of this article is to undertake a holistic review of the 
aetiopathogenesis of CD in which historical concepts are integrated 
with recent discoveries.
The bowel mucosa, an interface between faeces and the 
tissues
The distal ileum and colon contain >1011 bacteria per gram of 
faecal material2, which pose an immediate threat to life if they pen-
etrate into the underlying tissues. The bowel microflora are isolated 
by a thin film of mucus and a single layer of columnar epithelial 
cells with a surface area of approximately 32m2,3. The require-
ment for the absorption of fluids and nutrients by the bowel mucosa 
means that the bowel lining cannot simply be a tough impermeable 
barrier, and as a consequence provision must be made to defend the 
vulnerable mucosal epithelial cell layer against its contents. Mucus 
secreted by goblet cells forms a continuous, weak, viscoelastic gel, 
lining, 5–500 μm thick4. In addition to acting as a physical bar-
rier and lubricant, the mucus is the site of action of a variety of 
antimicrobial mechanisms including secretory IgA, antimicrobial 
enzymes and peptides5 and H2O2 generated by the DUOX elec-
tron transport chain6. Despite these barriers, the separation of the 
tissues from the gut microbiome is not absolute, and even in health 
the mucosa is constantly penetrated by relatively small numbers 
of enteric organisms and soluble microbial products that gain 
access into the tissues7–10. Scattered amongst the epithelial cells 
overlying lymph follicles are Microfold (M) cells11,12, a unique 
intestinal epithelial cell (IEC) subset that are highly specialized for 
the phagocytosis and transcytosis of gut lumen macromolecules, 
particulate antigens and pathogenic or commensal microorganisms, 
which they transfer across the epithelium to mucosal macrophages 
and dendritic cells. This slow, constant, transit is important for the 
development, priming and maintenance of a potent immune system 
in the submucosa13–15. The protective role of the bowel immune sys-
tem must be combined with tolerance to ingested antigens and com-
mensal organisms to maintain homeostasis in a healthy bowel.
The immune system in the bowel
The bowel is the interface between a dense population of microbes 
and the immune system. Although an in depth review of the 
immune system in the bowel is well beyond the scope of this review, 
it is important to briefly cover this subject because defects in innate 
immunity are central to the development of CD whereas aberrant 
adaptive immunity causes bowel inflammation of a very different 
type, and a range of largely inaccurate animal models of CD.
Adaptive immunity. Most of what is known of classical adaptive 
immunology relates to the immune system of the bowel, but there 
are in addition some specialised features unique to the intestinal 
mucosa16–18.
The mucosae and exocrine glands harbour the largest activated 
B-cell system of the body, amounting to some 80–90% of all 
immunoglobulin (Ig)-producing cells in humans19. The major 
product of these lymphocytes is polymeric (p)IgA (mainly dimers) 
with associated J chain. Both pIgA and pentameric IgM contain 
a binding site for the polymeric Ig receptor (pIgR), or secretory 
component (SC), which is a requirement for their active external 
transport through secretory epithelia into the overlying mucus19.
M cells, and intestinal dendritic cells, that phagocytose bacte-
ria interact with B and T cells in the Peyer’s patches, inducing B 
cells to produce IgA directed against intestinal bacteria20. IgA+ B 
cells home to the intestinal lamina propria and secrete IgA that is 
transcytosed across the epithelium and deposited on the apical sur-
face. The transcytosed IgAs bind to luminal bacteria, preventing 
microbial translocation across the epithelial barrier21,22.
After the initiation of the immune response by antigen processing 
and presentation to B and T cells in Peyer’s patches, primed 
lymphocytes leave the mucosa via the thoracic duct. Finally 
they migrate back to the mucosa where they exert effector 
functions.
There has been considerable recent interest in IL-23 and IL-17 
in relation to the aetiology of CD. Il-23 is secreted by macro-
phages and dendritic cells and transforms naïve T cells into 
Th (T-helper) 17 cells, and promotes their expansion and 
maintenance23, and they then produce IL-17, IL-21 and IL-2224. 
IL-17 induces numerous cell types including T-cells, mast cells, 
macrophages, neutrophils, keratinocyte, and natural killer cells 
to produce a raft of pro-inflammatory mediators including IL-1b, 
IL-6, IL-8, IL-11, Gro-α, G-CSF, GM-CSF, IL-4, IL-5, IL-13, 
IgE, and eotaxin25. An important outcome of this cytokine cas-
cade appears to be the recruitment of neutrophils to inflammatory 
sites26. Despite the apparent importance of IL-17 for intestinal bar-
rier function27 and for diverse pro-inflammatory activities, there 
must be considerable redundancy in the pro-inflammatory reper-
toire as defects in the IL-17 pathway are associated with a very 
narrow predisposition to disease in the form of mucocutaneous 
candidiasis28. None of the hundreds of patients with this condition 
had CD29.
IL-17 has been considered to be detrimental in CD as a conse-
quence of its apparent pro-inflammatory actions. It is therefore 
of interest that a trial of the treatment of CD with monoclonal 
antibodies against IL-17 had to be stopped because of the 
deterioration of the patients’ condition30.
      Amendments from Version 1
The section entitled Summary of outcome of GWAS studies in CD 
has been modified in accordance with the suggestions of Referee 2. 
Additional references have also been added. 
See referee reports
REVISED
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Adaptive immunity in the bowel protects against commensal 
organisms, or those previously encountered in infections that were 
successfully overcome. This is accomplished by the production of 
a barrier of secreted IgA that permeates the lining mucus layer and 
by the production of specific IgG and IgM that opsonise penetrat-
ing organisms for phagocytosis. Immunity to pathogenic bacteria 
like Salmonella, Shigella, Vibrio cholera and Escherichia coli is 
generally not very potent or long lasting, which, together with the 
propensity of bacteria to mutate, makes vaccines relatively ineffec-
tive31,32. A degree of immunity does develop as a result of repeated 
reinfection in endemic areas but because this is not permanent, it is 
gradually lost after emigration to cleaner environments, which 
might be an important factor in relation to the subsequent trigger-
ing of CD by infection in individuals moving from regions of low 
to high prevalence of this condition.
Innate immunity. The submucosa of the bowel is particularly 
vulnerable to microbial invasion if the mucosal barrier is breached 
as large numbers of organisms can achieve rapid access and the 
conditions are conducive to microbial proliferation. There is 
inadequate time for adaptive immunity to take effect and reli-
ance must be placed on the innate system to contain and eliminate 
potentially harmful stimuli. At its heart this means the rapid and 
florid release of pro-inflammatory cytokines from lamina propria 
macrophages33, recruited from blood monocytes34, mast cells35,36, 
eosinophils and innate lymphoid cells37–39 when activated by bowel 
contents. Paneth cells are specialised intraepithelial secretory 
epithelium of the small intestine that reside in small clusters at 
the base of crypts of Lieberkühn in the small intestine. Large 
secretory granules in these cells contain a wide variety of proteins, 
the most abundant of which are antimicrobials such as the alpha 
defensins that are discharged into the crypt lumen. These effec-
tor molecules also diffuse from the crypt and disseminate into the 
mucous layer that overlies the mucosal epithelium, where they 
contribute to the mucosal antimicrobial barrier40.
Pro-inflammatory cytokines induce changes in the microvascu-
lature41,42 leading to the extravasation of plasma proteins and to the 
recruitment of neutrophils43. A critical concentration of neutrophils 
is required to eliminate invading bacteria44 and immediately after 
bacterial penetration of the mucosa there is direct competition 
between bacterial replication and neutrophil recruitment and bacte-
rial phagocytosis and killing. In the absence of specific antibodies, 
uptake of the foreign material is enhanced by non-specific opsonins 
like pentraxins, collectins and complement45. The neutrophils then 
undergo apoptosis or necrosis and the purulent collection is most 
probably discharged into the bowel lumen, with the residual debris 
being phagocytosed and cleared by macrophages46.
Bowel inflammation in very early onset Inflammatory Bowel 
Disease (IBD)
Bowel homeostasis requires an intact mucosal barrier, itself 
requiring the integrated function of many different cell types and 
molecules, and the largest collection of immunological cells in 
the body to present an integrated defence against the 
intestinal microbiome. It is therefore not surprising that defects 
in genes coding for proteins required for the integrity of this 
barrier, or for normal immune surveillance, manifest as mucosal 
inflammation.
As might be expected, these conditions present very early in life, 
and because they affect the mucosa as a whole, they result in a 
diffuse, non-specific inflammation, predominantly in the large 
bowel where concentrations of bacteria are highest. Uhlig et al. 
(Figure 1)47 found that about 5% of their cases of IBD had infantile 
or very early onset disease. This will represent a much higher 
proportion of cases than that occurring in the general population, 
because most cases of IBD occur in adults and are handled in non- 
specialist facilities, whereas rare inherited diseases gravitate to 
specialist centres like those of Uhlig and his co-authors. The 
monogenic lesions identified provide important identifiers of the 
molecules required for bowel integrity and adaptive immunity.
Mutations in the barrier function genes such as COL7A1, 
FERMT1, TTC7A and ADAM17 generally result in infantile 
bowel dysfunction and inflammation.
Figure 1. Age of onset of IBD-like symptoms in patients with 
monogenic diseases. Multiple genetic defects are summarized in 
the group of atypical Severe Combined Immunodeficiency (SCID), 
Hoyeraal–Hreidarsson syndrome, Chronic Granulomatous Disease 
(CGD), and Hermansky–Pudlak syndrome. By comparison, an 
unselected IBD population is presented (Oxford IBD cohort study; 
paediatric and adult referral-based IBD cohort, n = 1605 patients 
comprising CD, Ulcerative Colitis (UC), and IBD unclassified [IBDU]). 
Symbols represent individual patients. Bars represent the age range 
of case series if individual data were not available. Reproduced from 
47 with permission from the publisher.
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The severe immunodeficiency syndromes such as atypical Severe 
Combined Immunodeficiency (SCID) and Immunodysregulation 
Polyendocrinopathy Enteropathy X-linked Syndrome (IPEX) also 
generally have a very early onset and also do not have intestinal 
changes characteristic of either CD or UC. In contradistinction, the 
neutrophil defects, exemplified by Chronic Granulomatous Disease 
(CGD), and including Hermansky-Pudlak, congenital neutrope-
nia and leukocyte adhesion deficiency all have a CD phenotype 
clinically, endoscopically and histopathologically, with a lot 
of perianal disease and granulomata evident on biopsy48. The 
neutrophil defects generally present later than the abnormalities 
of mucosal barrier function, or the severe immunological diseases.
Mutations in the genes coding for IL-10 and IL-10 receptor both 
present very early in life, as seen in mucosal abnormalities and 
immunodeficiencies, and exhibit the bowel phenotype character-
istic of defective neutrophil function. These observations would 
appear to be at variance with the prevailing view that IL-10 down- 
regulates macrophage function, and that the bowel inflamma-
tion in its absence is a manifestation of uncontrolled macrophage 
activation49. IL-10 does appear to be required for normal intestinal 
development. Multisystem abnormalities were observed in the 
original description of the IL-10 knock-out mouse50 in which there 
was a general enterocolitis with greatest abnormalities in the duo-
denum and jejunum, not locations associated with a high burden 
of commensal bacteria. Under specific-pathogen free (SPF) con-
ditions the bowel lesions persisted, but were limited to the proxi-
mal colon. In addition the mice exhibited a severe growth defect, and 
were severely anaemic with a paucity of erythroid precursors in the 
bone marrow that was filled with myeloid precursors. The anaemia 
was unrelated to the extent of bowel involvement. These pheno-
typic features indicate that IL-10 is required for the normal growth 
and development of the bowel mucosa and haemopoetic tissue, in 
addition to its suppressant effect on macrophages51.
The observed phenotype of patients with IL-10 and IL-10 recep-
tor deficiency is in keeping with that of defective neutrophil 
function49,52. Almost all the patients showed evidence of bacterial 
infections in the form of folliculitis, and ear and respiratory tract 
infections. Most revealing was the almost universal occurrence of 
perianal disease with abscesses, fissures and fistulae that are highly 
characteristic of the neutrophil deficiency diseases like CGD53,54, 
Hermansky-Pudluck55 and glycogen storage disease 1b56. If the 
IL-10 deficient phenotype results from the impairment of normal 
cellular development and an immunodeficiency rather than an 
excessive, unregulated, macrophage response as proposed, then it 
might be expected that treatment with immunosuppressive therapy 
would be ineffective, which was indeed found to be the case52.
It is also noteworthy that bowel inflammation is not a feature of 
the classical autoinflammatory diseases in which deregulated 
macrophage activation is a feature. These diseases include 
cryopyrin-associated periodic syndrome (CAPS)57 in which acti-
vating mutations in the NLRP3 gene result in increased excretion 
of IL-1β excretion and other pro-inflammatory cytokines, and the 
haemophagocytic syndrome58, in which the uncontrolled activa-
tion of antigen-presenting cells (macrophages and histiocytes) and 
T cells produces an exaggerated inflammatory response and 
cytokine storm.
Of mice and men - mouse models of “IBD”
Mouse models of IBD have been extensively reviewed in the 
literature59–61. These models are very important because they are 
depended upon by clinicians and scientist trying to understand 
the causes of these diseases, and by the pharmaceutical industry 
attempting to produce drugs with which to treat them.
Induced inflammation. In general, impairment of the innate 
immune system as in mouse models of CGD or Wiscott-Aldrich 
does not result in the spontaneous development of bowel inflamma-
tion, although they do exhibit an exaggerated response to insult62.
Predisposition to bowel inflammation may be exposed by 
reducing intestinal barrier function, thereby allowing access of 
the contained microbiome to the underlying tissues. Barrier 
function can be compromised through the genetic manipulation of 
proteins required for the production of mucus or the maintenance 
of epithelial integrity63 or by the use of chemicals or infectious 
agents.
Chemical agents employed for this purpose fall into three main 
groups. Those that produce direct damage to the mucosa such as 
dextran sodium sulphate (DSS64), acetic acid and carrageenan65. 
The second group are those such as Haptens (e.g. 2, 4-Dinitrochlo-
robenzene (DNCB66) or Dinitrobenzene sulphonic acid (DNBS)) 
that induce an immune response. Finally infection with bacteria 
such as Salmonella, E.coli or Citrobacter, or parasites60 may be 
utilised.
Genetic models. The advent of gene targeting technology has 
provided immunologists with powerful tools with which to 
explore the immune system. In the course of investigating its 
diverse components, hundreds of different genes have been 
knocked-out, some of which resulted in the spontaneous devel-
opment of bowel inflammation. Because of this, these mice have 
been proposed as models of IBD.
Prominent examples of such mice include the IL-267, T cell 
receptor (TCR)α/β68, and IL-1050 knockout models. With the 
exception of IL-10-deficient mice, which possess some features 
of human CD, the majority of these models have diffuse colonic 
inflammation. A strain of mouse (TnfΔAREmice) was developed in 
which elements of the tumour necrosis factor (TNF) gene that are 
required to restrict the overproduction of this cytokine have been 
removed. In their absence the mice exhibit sustained over produc-
tion of TNF which results in a diffuse arthritis and terminal ileal 
and caecal inflammation69. IL-17 and IL-22 deficiency exacerbate 
induced colitis70.
Spontaneous models. The C3H/HeJBir model of colitis was 
discovered by chance when mice in breeding colonies developed 
loose bowel actions71. The pathology is characterised by sponta-
neous and chronic focal inflammation localised to the right colon 
and caecal region although not involving the small intestine. The 
colitis occurs in young mice and tends to resolve with age, without 
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recurrence. The genetic mechanisms underlying these abnormali-
ties remain to be identified.
SAMP1/Yit mice were developed from senescence-accelerated 
mice72. They spontaneously developed ileitis and gastritis even 
under germ free conditions. The underlying aetiology is unknown 
but there is some evidence that the primary defect lies in the 
epithelial cell barrier and that B cells appear to play a role in the 
pathogenesis of inflammation at both sites73.
Adoptive transfer. One of the most commonly cited models for 
the study of the role of T lymphocytes in bowel inflammation in 
mice (as a proposed model of CD) is the adoptive transfer model 
in which T cells are transfused into SCID mice74, result-
ing in bowel inflammation. By observing the effects of var-
ying the populations of cells infused, conclusions have 
been drawn as to the regulatory interaction of the vari-
ous cell populations. It is important to understand that these 
host SCID mice have hardly any B or T lymphocytes and, as 
their name suggests, are hypogammaglobulinaemic and severely 
immunocompromised. In the CD45RBhigh transfer model, first 
described by Morrissey75 a subset of lymph node CD4+ T-cells, 
expressing high levels of the marker CD45RB (CD45RBhi), were 
injected into SCID mice. The mice developed a wasting disease 
accompanied by massive hyperplasia of the intestinal mucosa 
with a dense infiltration of lymphocytes thought to be due to “an 
augmented, unregulated reaction towards higher levels of luminal- 
derived bacteria or bacterial products”. These changes were not 
seen when the animals were infused with unfractionated CD4+ 
or CD45RBlo cells, indicating that the extreme reaction to bacte-
rial products76 by the CD45RBHi cells could be controlled by the 
CD45RBlo cells. Soon after, similar experiments were conducted by 
Powrie and colleagues77,78 who observed the same pathological 
changes in the bowel which they equated to those changes found 
in “inflammatory bowel disease” in humans. They showed that 
these changes could be prevented by antibodies to interferon-
gamma and by recombinant IL-1078, and identified the cells in 
the CD45RBlo population responsible for controlling CD45RBhi 
induced inflammation as the population of suppressor T-cells 
called T-reg cells79.
These observations and their extrapolation to human IBD sparked 
a large body of work into the role of regulatory T cells in the 
pathogenesis of IBD. Over the past decade, multiple groups 
have failed to find abnormalities in these cells in the intestines or 
blood of patients with IBD80, not altogether surprising given 
the extreme artificiality of the animal model from which their 
presumed role in human disease was derived.
These mouse inflammation models are undoubtedly of great value 
in dissecting out immunological mechanisms and attributing roles 
to specific cellular populations and their associated cytokines. 
However, equating genetic mutations leading to bowel inflam-
mation in mice with causal mechanisms of diseases in humans 
can have serious consequences as it may misdirect clinicians and 
scientists as to the underlying pathophysiology, and mislead 
pharmaceutical companies as to the relevant biological pathways 
against which to attempt to develop drugs. On the other hand, 
mouse models can be of great value when the problem is turned 
the other way around and they, and other animals like zebrafish, 
are used to validate the causality of molecular lesions found in 
association with disease in humans, for example those involving 
IL-1061 and ADAM1781.
Classification of IBD
“Medicine is learned by the bedside and not in the classroom. 
Let not your conceptions of disease come from words heard in 
the lecture room or read from the book. See, and then reason 
and compare and control. But see first.”
Sir William Osler
IBD has referred to CD and UC because both can largely affect the 
colon and terminal ileum, however, although there may be overlap 
at the interface of these two conditions, their classical manifesta-
tions are quite different82,83. They are both syndromes, rather than 
specific diseases, where common clinical pictures are united by a 
common set of diagnostic criteria produced by similar pathophysi-
ological mechanisms.
CD84 usually involves the terminal ileum, and the caecum and 
colon to a variable extent, where the lesions are patchy, known 
as “skip lesions”, and associated with strictures, and fistulae 
between the bowel and other loops of bowel, the skin, and pelvic 
organs like the bladder and vagina. Outside the bowel, at the sites 
of transmural inflammation, the mesenteric adipocytes hypertro-
phy, covering the exterior of the bowel with a layer of protective 
fat, a process known as fat wrapping. Anal disease affects about 
40% of these patients85 exemplified by abscess, fistulation and skin 
tags. The inflammation is described as transmural, extending deep 
into the wall of the bowel, and contains diagnostic granulomata, 
collections of macrophages which represent a characteristic tissue 
response to retained foreign material. “The basic etiological factor 
in the case of all granulomas is probably the presence of a nidus of 
insoluble material which, if small enough is ingested by phagocytic 
cells, or, if too large, remains extracellular”86. The central macro-
phages in these granulomata are surrounded by lymphocytes.
UC is very different in that it starts at the rectum and extends 
proximally, although occasionally, when it involves the whole 
large bowel there can also be involvement of the terminal ileum, 
a condition known as “backwash ileitis”. The inflammation in 
UC is superficial, being limited to the lamina propria, and the 
histological hallmarks are crypt abscesses and depletion of goblet 
cells that normally contain mucus.
Although a syndrome, the diagnostic features of classical CD are 
quite precise, and very different from the very rare cases of very 
early onset IBD, and the vast majority of genetically abnormal 
mice, both characterised by bowel inflammation rather than the 
clinical criteria used to diagnose CD or UC.
The three phases of Crohn’s disease
A unifying model of CD pathogenesis has been proposed in which 
this condition develops in three temporally distinct phases87: 
• The trigger - gastrointestinal infection;
• A defective response to the consequences of this infection;
• A subsequent prolonged chronic inflammatory adaptive 
immune response.
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Figure 2. The immunopathogenesis of CD occurs in three temporally distinct stages. Penetration of luminal contents into underlying 
tissues occurs in stage 1, which may be facilitated by environmental factors such as infection, or inherent defects in the mucosal barrier. In 
healthy individuals, resident macrophages secrete pro-inflammatory cytokines in response to this material, resulting in neutrophil accumulation, 
clearance of the material, and thereby resolution. In CD patients, defective secretion of pro-inflammatory cytokines by macrophages results 
in impaired neutrophil influx and clearance of foreign material (stage 2). Subsequently, chronic inflammatory responses (stage 3) will be 
triggered, giving rise to the characteristic features of the CD lesion. From 87 Figure 1 (reproduced with permission from the publisher).
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Figure 3. Increasing incidence of CD in several countries over time. Reproduced from 94 (with permission).
The trigger - Breeching the mucosa – The infectious 
environmental factor
Epidemiology. There is strong evidence for the role of an infec-
tious environmental factor in the pathogenesis of CD. This is most 
obviously seen when populations or families emigrate from one 
country to another. A high proportion of family members have 
been documented as developing the disease after moving from 
Morocco to Belgium88, from Albania to Greece89 and from India 
to Canada90. After being imported into the household enteric 
infections can spread to family members91. At a population level, 
an increased incidence of CD has been described in recent 
immigrants from Ethiopia to Israel92, and from Eastern European 
and Iraq to Sweden93.
The epidemiology of CD has been the subject of a large body of 
work and multiple reviews. Most pertinent to this paper are issues 
concerning environmental influences, several of which are clearly 
associated with CD as outlined below.
Temporal trends. There has been a steep rise in the incidence 
of CD over the last few decades in economically advanced 
countries across Europe, North America and Australasia94–96. This 
is not purely an effect of increasing economic affluence because 
the incidence of CD is much lower in other economically advanced 
countries such as Japan and South Korea, although the incidence is 
now also rising in these countries97,98.
CD is generally more common in urban females of higher 
socioeconomic status96, with a male to female ratio of about 1.5–2:1.
The difference in prevalence of CD by country could be partly 
explained by genetic factors; however, evidence from migration 
studies emphasise the importance of the environment. A limited 
number of studies investigating the incidence of CD among recent 
immigrants have been undertaken. The most informative of these 
assessed the risk of IBD in first- and second-generation immi-
grants to Sweden from many different countries93. They found that 
overall risk of CD was lower in many groups of first-generation 
immigrants than in the native-born Swedish reference group but 
that in most groups of second-generation immigrants these 
decreased risks disappeared, and in some cases even exceeded those 
in the native Swedish population. First generation Middle East-
ern immigrants to Australia developed CD at a much later age 
(∼57 years) than the second-generation who developed it at about 
28 years of age, roughly the standard age in Western society99. CD 
is very rare in Ethiopia but emerged in Ethiopian Jews migrating 
to Israel after a median lag of about 12 years after arrival92. CD 
is also more common in Bangladeshi immigrants to England100. 
Combined, these studies imply that immigrants from underdevel-
oped countries initially have a resistance to CD that wanes over the 
subsequent decade or so.
Infection. Infection has long been considered to cause CD. Attempts 
were made to transmit a CD agent from gut or lymph node 
tissue of patients to wild-type or immunodeficient mice101. More 
granulomata were found in the mice receiving CD tissue, but that 
could have been due to the fact that the inflamed tissue contained 
enteric organisms or inflammatory cytokines. In the first descrip-
tion by Danziel in 1913 of what was later to be called Crohn’s dis-
ease, the similarity between “chronic interstitial enteritis” and Johne’s 
disease in cattle102, which is caused by infection with 
Mycobacterium avium paratuberculosis, was commented upon103. 
Evidence that this agent was also responsible for human CD has 
been extensively sought104 but has not been forthcoming105,106.
Several prospective studies have followed the course of patients 
after infections with enteric organisms and all have found an 
increased incidence of IBD as compared with uninfected control 
subjects107–111. In one of these110 the risk was similar whether or not 
an infecting agent was identified, suggesting that it was the damage 
to the bowel rather than a specific infection that was important.
Enteric infections are most commonly caused by viruses, 
particularly Norovirus112 and by Campylobacter, Salmonellae, 
Shigella, Entamoeba histolytica, Cytomegalovirus and Yersinia113,114. 
Particular attention has been paid to an adherent-invasive subgroup 
of E. coli, that has been linked to the development of CD115–117. 
The natural lesions produced by these organisms might provide 
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some insight into those most likely to trigger CD. Norovirus 
mainly affects the proximal small intestine112,118 and Amoebic and 
Salmonella infections generally produce a diffuse colitis whereas 
the other infections result in lesions located in the terminal ileum 
and colon, with a patchy distribution, similar to those of the lesions 
of CD119–126.
Whereas the incidence of most bacterial gastrointestinal infec-
tions is steady or falling, that induced by the commonest bacte-
rial pathogen, Campylobacter is increasing in countries like North 
America, Europe, Scandinavia, Australia and New Zealand and 
Japan127 (Figure 4). This could be because this organism is a 
common contaminant of poultry, the consumption of which is 
increasing in these countries, however, broiler flocks are heavily 
contaminated with both Campylobacter and Salmonellae128 and the 
incidence of infection by the latter is steady or falling (Figure 4).
“Relapses” in cases of IBD have been reported to be associated with 
infections with various organisms including Clostridium difficile, 
Shigella, Salmonella, Campylobacter, E. coli and Listeria129. 
These subsequent infections might be inducing the development of a 
novel set of Crohn’s lesions in a predisposed bowel, rather than 
recrudescence of the original disease, as a result of infection by 
different organisms. These subsequent infections could be predis-
posed to by the immunosuppressive treatments commonly used in 
this condition including corticosteroids, cytotoxic and biological 
agents.
Most gastrointestinal infections do not generally produce homoge-
neous mucosal damage but lead to focal areas of ulceration125,126, 
often in the ileocaecal region of the bowel. Because infection with 
invasive gastrointestinal pathogens is a stochastic process130, the 
age at which this occurs is highly variable, as is the outcome after 
the infection, which will depend upon the severity of the infection, 
extent of ulceration, quantity of bowel contents gaining access to 
the tissues and to the effectiveness of the innate immune response.
The microbiome, prebiotics, probiotics and faecal transplants. 
In the search for possible causal infectious agents, stool samples 
from CD patients have been extensively cultured and examined 
without a positive result (see for example 131). This is not entirely 
surprising because the average time from the onset of symptoms 
to diagnosis of CD is over six months132 by which time an infec-
tious organism will have been eliminated if it was a triggering agent 
rather than the cause of a chronic infection. With the advent of next 
generation 16S rRNA gene sequencing the phylogeny and tax-
onomy of samples from complex microbiomes can be determined 
without the need for them to be viable or culturable. Dysbiosis of 
the faecal microbiome is well recognised in CD133,134, with a 
decrease in the abundance and diversity of the Firmicutes phylum 
and an increased abundance of Proteobacteria, and alterations in 
the fungal composition135. Differences were also found between the 
microbiotas of CD patients with ileal and with colonic disease136. 
This could reflect an epiphenomenon secondary to the disease 
process. Major alterations in the microbiota are induced by 
diarrhoea137, enteral nutrition138, antibiotics139, which most of 
these patients receive140, and by iron therapy141 which is often 
prescribed because these patients are generally anaemic. In gen-
eral, gut and mouth microbiomes display universal dynamics, 
unlike microbial communities associated with certain skin sites 
that are probably shaped by differences in host environment142.
Because CD predominantly occurs in those regions of the bowel 
with a high bacterial count, and given the differences in the 
microbiotas in CD described above, attempts have been made to 
alter the intestinal microbiota in the treatment of this condition. 
Prebiotics are typically non-digestible, fibre rich materials, which 
stimulate the growth or activity of advantageous bacteria that 
colonize the large bowel, whereas probiotics are live microorgan-
isms that are directly administered by mouth. Neither prebiotics 
nor probiotics have been shown to be beneficial in CD143–145. An 
alternative means of directly altering the intestinal microbiota is 
by faecal microbiota transplantation, the transfer of faeces from 
a healthy donor, to restore the intestinal microbiota of a diseased 
individual. Whilst this is a logical treatment for Clostridium difficile 
infection, which generally develops in a colon depleted of its 
natural microbiome by antibiotics, it has not been found to be 
effective in the treatment of CD146,147.
Figure 4. Number of recorded infections caused by Salmonella, Campylobacter, Yersinia enterocolitica and VTEC, 1980–2012. 
EPI-NEWS 12, 2013 from Statens Serum Institut, Denmark (reproduced with permission).
Page 8 of 35
F1000Research 2016, 5:2510 Last updated: 25 DEC 2016
The Hygiene Hypothesis. The considerable increase in the inci-
dence of CD in developed countries in recent decades148 has been 
attributed to immunological changes to alterations in the environ-
ment as outlined in the Hygiene Hypothesis149. This hypothesis150 
was first described by Strachan in 1989 who stated that “over 
the past century declining family size, improvements in house-
hold amenities, and higher standards of personal cleanliness have 
reduced the opportunity for cross infection in young families. This 
may have resulted in more widespread clinical expression of atopic 
disease”151. Subsequently modern living conditions have been held 
responsible for the increasing incidence of a variety of so called 
“auto-immune” diseases, including CD, which have been attributed 
to exposure a reduced load of microbes of decreased diversity. Cer-
tainly CD is less common in rural societies where there is exposure 
to animals, pets and soil, bedroom sharing is more common, and 
there is less access to hot water for ablutions99.
According to this theory, standards of hygiene are lower in lower 
socioeconomic societies, leading to a greater abundance and variety 
of gastrointestinal pathogens. This would lead to a high incidence 
of gastrointestinal infections in infancy and childhood, resulting in 
death152 or immunity153. CD is very uncommon in underdeveloped 
societies in Asia154, South America155, China156 and sub-Saharan 
Africa157 and the increase in its incidence is closely associated with 
the improvement in income and living standards. Enteric infections 
are endemic in these developing societies in which diarrhoea is a 
major cause of death in children less than 5 years of age158–160. The 
population in underprivileged societies also host a large burden of 
gastrointestinal helminths161 and the low incidence of CD recorded 
in developing countries has been attributed to the high rates of  gas-
trointestinal infections with these organisms162. Helminthic infec-
tion was found not to be protective against CD in Denmark163 and 
the outcome of several trials of iatrogenic infection with helminths 
as therapy for CD are awaited, but current evidence does not sug-
gest that they will be efficacious162,164.
Immunity to enteric organisms is transient165–167, and may be strain 
specific168, and would be boosted by frequent reinfection in less 
advanced countries. This herd immunity would be lost over time 
after immigration to socially advanced, cleaner, societies, which 
would accord with the later age of onset of CD in first generation 
immigrants. One could envisage a situation in which the population 
of more socially advanced countries are living under increasingly 
hygienic conditions and are exposed to a less diverse repertoire of 
the enteric microorganisms capable of producing gastrointestinal 
infection. With less frequent gastrointestinal infection, the bowel 
is uninflamed, with less primed macrophages, mast cells and den-
dritic cells in the lamina propria and adaptive immunity is more 
restricted, and relatively feeble, through the lack of repeated boosts 
by infection, making the bowel vulnerable to attack by a novel or 
virulent organism.
If we postulate that the trigger for CD is enteric infection, how can 
the fact that the incidence of food-borne gastroenteritis is fairly 
steady in most developed countries169 be reconciled with the rapidly 
increasing incidence of CD? Due to greater regulation and control 
of food production and distribution the incidence of foodborne 
outbreaks of disease have remained steady or have declined170–172.
It is important to consider the age distribution at which patients 
present with Crohn’s disease. It rises to a peak at between 
20 and 30 years of age after which it demonstrates a steady 
decline, a pattern that is remarkably consistent, and very different 
from that of UC, across the geographical spectrum98,173–175.
The peak incidence, generally at a later age than puberty, coincides 
with a stage in life accompanied by major lifestyle changes. These 
include the movement of individuals out of the family home, in 
which the ambient microbiome is likely to be relatively stable, into 
environments in which the risks of exposure to infection are much 
greater. The main two ways in which young adults are exposed to 
infectious enteric organisms is through the ingestion of contami-
nated food or fluids, or by person to person contact, the risk of 
both being increased by travel to places where exposure to novel 
organisms is more likely.
Sexual transmission
Although enteric infections are generally considered to be 
foodborne, only about one half are in fact transmitted in this 
way177, most of the rest being transferred by person to person con-
tact. Sexual transmission is worthy of consideration as a means 
of transmission of faecal organisms between individuals because, 
as might be expected, the peak age for the acquisition of sexually 
transmitted diseases is very similar to that of CD (Figure 5).
Epidemiological studies from developed countries have reported 
an increasing prevalence of invasive infections by Entamoeba 
histolytica178, Shigella179, Cryptosporidia180 and Campylobacter181, 
among men who have sex with men (MSM), which is not surpris-
ing because of the increased risk of exposure to coliform organ-
isms by oral, anal and oro-anal sexual practises182. The ingestion 
of as few as 10 virulent Shigella organisms can confer full-blown 
dysentery183. It is easier to establish the causality of infectious 
outbreaks in these groups of individuals as compared with the gen-
eral population, because they fall into more readily identifiable 
groupings which facilitate the epidemiological studies. It would be 
important to establish the incidence of CD in MSM, but diagnosis 
in these individuals is complicated by the relatively small propor-
tions of individuals attending gastroenterology facilities, the pres-
ence of compounding factors such as “gay bowel”184 and of sexually 
transmitted diseases like lymphogranuloma venerium185 that can 
masquerade as CD.
Given that oral and oro-anal sexual practises have been demon-
strated to be responsible for the transmission of enteric infections in 
MSM, they must also pose a risk in other populations186,187. Although 
rectal bacterial flora are present on the perineum of both sexes188 
and in the vagina189 it is unlikely that an increase in gastrointestinal 
infection would result from vaginal intercourse alone. Only about 
5% of the sexually active individuals in countries like Britain190 and 
the United States191 are not heterosexual. In the heterosexual com-
munity the anal sex is practised by 30 – 40% of the population in 
England (Figure 6) and North America, and fellatio and cunnilingus 
are almost universal190,192. In England the participation in anal sex 
has almost doubled over the last three decades, a similar increase to 
that of the incidence of CD. In terms of absolute numbers, approxi-
mately seven times more women than homosexual men engage in 
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Figure 5. (A) The age distributions of Crohn’s disease and ulcerative colitis in several European countries. (Reproduced from 173 with 
permission from the publisher). (B) Global age-sex distribution of new HIV infections176 (reproduced with permission).
Figure 6. Heterosexual sexual practices in Britain. Redrawn from from the three National Surveys of Sexual Attitudes and Lifestyles190. Each 
line connects values for the same birth cohort at different ages.
A
B
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unprotected receptive anal intercourse193. In addition, the ratio of 
homosexual to bisexual men is about 3:1, and the latter can act as 
“bridgers”, transmitting infections from men who have sex with 
men into the heterosexual community194.
Those countries with a high standard of living and low rate of 
CD like Japan97, Taiwan, China195 Korea98, Saudi Arabia196 and 
Malaysia83, appear to have low rates of heterosexual anal sex http://
www.data360.org/pdf/20070416064139.Global Sex Survey.pdf197 
and in these countries the sex ratio of the disease, which is com-
moner in females than in males96 in Western countries, is reversed, 
implying that men are particularly vulnerable to infection in these 
places. This does not appear to be due to a reporting bias because 
the sex ratio of UC in these countries matches that of Europe and 
North America.
Monogamous heterosexual couples develop complementary 
microbiomes198,199 which would suggest that the highest risk to 
infection of either partner through sexual contact would be in the 
early stages of a relationship, and that the risk to an individual 
would be related to the numbers of sexual partners, some of whom 
might be asymptomatic carriers of pathogenic organisms200–202.
Clearly the above arguments are conjectural and their validity will 
require validation through sound sociological, epidemiological and 
microbiological investigations.
Four other factors, smoking, antibiotics, appendectomy and inva-
sive pneumococcal disease have positive correlations with the 
incidence of CD.
Smoking 
Smoking of tobacco is the strongest environmental influence 
on CD, roughly doubling the incidence203 and relapse rate204. 
Smoking and nicotine impair intestinal205,206 and gastric207 mucosal 
blood flow. Adequate blood flow is central to the development of an 
effective acute inflammatory response. Smoking also reduces levels 
of acute inflammatory cytokines in the bowel wall208 and lumen209 
in patients with CD.
Antibiotics and appendectomy 
There is an increased frequency of antibiotic use in CD prior to 
diagnosis96,210. The increased frequency of antibiotic use may 
be explained by an increased number of childhood bacterial 
infections. Similarly, an increased frequency of tonsillectomies210 
has been reported in CD and this may be an indication of recur-
rent pharyngitis. A further indication of a predisposition to infec-
tion in CD comes from the demonstration that these patients are 
more susceptible to invasive pneumococcal infection211.
A history of a greater frequency of appendectomy in CD is also in 
keeping with an increased susceptibility to childhood infection in 
this condition96.
Phase two – a defective inflammatory response
“Any infectious agent associated with Crohn’s disease is likely 
to be a widely distributed organism to which some people react 
abnormally - that is, the disease is unlikely to show the characteristic 
features of an infectious disease212.”
As described above, there is very good reason to believe that 
the initiating lesion in CD is infection by one of a number 
of enteric pathogens. The key to comprehending how the 
pathological lesions of the disease then develop lies in 
understanding the response to that initial infection. The infection 
by the organisms described above is very unlikely to persist, or 
the causal connection would have been clearly established some 
time ago. This is also the reason that antibiotics are of only 
limited efficacy in the treatment of CD213.
These patients are unlikely to be unduly susceptible to infection by 
these organisms, or else the onset would occur earlier, and systemic 
disease would be expected, as occurs with Salmonellae when the 
interferon-gamma/IL-12 axis is disrupted214.
Immunoparesis of the acute inflammatory response 
is the underlying Crohn’s phenotype
The underlying pathology in Crohn’s disease is the ineffective 
manner in which the faecal material entering the tissues through 
the damaged mucosa is dealt with. Infective damage to the mucosa 
followed by the entry of faecal material with a bacterial count of 
greater than 1011 bacteria per ml into the tissues poses an existen-
tial threat that must be dealt with vigorously. This is accomplished 
by the acute inflammatory response, a non-specific local reaction 
to tissue damage that recruits the innate immune system. It 
includes the secretion of inflammatory mediators from mast cells 
and macrophages, complement activation, markedly increased 
blood flow, capillary dilatation and permeability, the deposition 
of a fibrin network, and most importantly in the context of CD, a 
massive influx of neutrophil leukocytes, highly motile phagocytes 
that ingest and kill invading bacteria and fungi and digest foreign 
organic material.
The underlying, and unifying, predisposition to the development 
of CD is a systemic incompetence of this acute inflammatory 
response. I will deal with the evidence supporting this immun-
oparesis in some detail because these experiments have been per-
formed on CD patients, and healthy control subjects, and in some 
cases patients with UC and represent a unique set of data that have 
not been repeated, possibly because of the invasive and uncomfort-
able investigations required to obtain them.
The delay in the recruitment of neutrophils to sites of trauma to 
the body by the innate immune response has been demonstrated 
in patients with CD in several different but complimentary ways. 
In 1976 I demonstrated that the accumulation of neutrophils in 
superficial abrasions on the arm called “skin windows”, was grossly 
deficient when compared with healthy subjects or patients with 
another chronic inflammatory condition, rheumatoid arthritis215. 
It was observed that “This abnormality of neutrophil function 
in Crohn’s disease appears to be secondary to a defective acute 
inflammatory response as the neutrophils themselves were found 
to behave normally on in-vitro testing. A weak acute inflammatory 
response to particulate or antigenic material in the bowel wall could 
result in the chronic inflammation observed in this condition.”
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The next in these series of experiments was conducted on the ileal 
and rectal mucosa, and again on the skin216. A small mucosal biopsy 
was taken from the ileum or rectum, and this was then followed 6 
hours later by a further biopsy of the previous biopsy site, to deter-
mine the extent of the inflammatory response induced by the initial 
biopsy trauma. Once again there was a major delay in the recruit-
ment of neutrophils in CD, and this was observed in both regions 
of the bowel. In addition to healthy subjects, control individuals 
with UC were studied and their neutrophil recruitment was normal. 
Trauma to the skin reproduced the impaired neutrophil recruitment 
into skin windows, as well as reduced secretion of IL-8 and IL-1β 
from them.
The direct injection of heat killed E.coli into the subcutaneous tis-
sues of the forearm of normal subjects was followed by profound 
rise in local blood flow. This was considerably impaired in CD, but 
not in UC. Blood flow is important in recruiting innate immune cells 
to sites of inflammation and this already paltry vascular response in 
CD would be further compromised by smoking tobacco217.
The third of these experiments directly measured the accumulation 
of neutrophils at the site at which E.coli had been injected subcuta-
neously, and the rate of clearance of these organisms. In this study 
peripheral blood neutrophils were purified from the individual 
under investigation, labelled with the gamma-ray emitting radioiso-
tope Indium-111218, and reinjected intravenously at the same time 
that unlabelled E.coli were injected subcutaneously into the fore-
arms. The rate of accumulation of the radioactive neutrophils over 
the site of the injected bacteria was determined219. A much smaller 
proportion of neutrophils were recruited to the injected bacteria in 
the CD subjects than in the HC or UC individuals (Figure 7).
The next step was to radiolabel the E.coli with Phosphorus-32 and 
to then determine the rate of clearance of the bacteria from the 
tissues. This was a two phase process in HC and UC subjects with 
a very rapid initial clearance lasting about 4 hours followed by a 
slower phase, with total clearance being achieved by 7 to 10 days. In 
the CD subjects, initial clearance was much less efficient and total 
clearance was markedly delayed and was predicted to last from sev-
eral weeks to infinity. This study showed unequivocally that colif-
orm bacteria are cleared less efficiently from the tissues than normal 
in CD. It might be considered that this delayed recruitment of neu-
trophils to bacteria in the tissues should predispose these individu-
als to an increased incidence of clinically evident infections, which 
is not an obvious manifestation of CD. The reason for this apparent 
discrepancy is that the numbers of bacteria injected into the tissues 
were required to reach a certain critical load before the clearance 
defect was unmasked (Figure 7e). In this study 106 organism were 
cleared normally whereas 107 were not, indicating that a significant 
bacterial load must enter the tissues before the clearance systems 
are overwhelmed. The bowel is the only location in the body where 
such a burden of microbes is readily available to enter the tissues.
Phase three - The consequences of the failure to clear 
intestinal contents from within the bowel wall
In the absence of an adequate acute inflammatory response and the 
complete clearance of the inciting agent by neutrophils, the retained 
foreign material produces a granulomatous inflammation220–222. 
E.coli, Streptococci and Listeria have been demonstrated 
immunochemically in macrophages, giant cells and lymph nodes 
of CD patients223, and E.coli DNA has been identified in Crohn’s 
granulomata isolated by laser capture microdissection224. The reten-
tion of this faecal material within the bowel leads to an intense 
adaptive immune response and the tissues become infiltrated with 
large numbers of T-cells. It is not therefore surprising that when 
actively inflamed CD tissues are biopsied, any number and variety 
of adaptive immune cells can be identified and immune mechanisms 
evoked in the pathogenesis of the condition. The macrophages and 
adaptive immune cells, reacting to the foreign antigenic material, 
will produce cytokines such as IL-1β and TNFα225,226 that lead to 
local inflammation and systemic symptoms227.
The clinical picture of an inflamed bowel containing large numbers 
of macrophages and T-cells228,229 has led to the erroneous belief that 
Crohn’s was an autoimmune disease80. It is however clear that the 
cytokines produced by these inflammatory foci in their response to 
foreign faecal material contribute to the local and systemic inflam-
mation, and failure of mucosal healing, as evidenced by the, often 
dramatic, responses to anti-TNF drugs. However, only about half 
the patients respond to this treatment, and in those that do the 
response is often partial and temporary230.
Chronic inflammation leads to fibrosis, or scarring231, which in 
a hollow muscular organ causes narrowing, or stricture forma-
tion. Under some circumstances the material in the bowel wall 
undergoes liquefaction, as may occur with tuberculosis232. This 
material then tracks to adjoining organs, possibly driven by the 
osmotic pressure produced by the breakdown of the organic mate-
rial within the abscess, and discharges into them. This can then 
produce fistulae233 between the these organs for example between 
bowel and bowel, bowel and skin, bladder or vagina. The perianal 
fistulae between the rectum and perineum are characteristic of 
CD and of immunodeficiencies of the innate immune system, 
particularly those of neutrophil function54.
This failure to clear organic material from the tissues offers an 
explanation for the false positive Kveim tests observed in CD234. 
The Kveim test235 was designed to diagnose sarcoidosis, another 
chronic granulomatous disease. The intradermal injection of a 
crude homogenate of an extract of sarcoid tissue, usually from 
lymph node, produced epithelioid cell granulomas in subjects with 
sarcoidosis, reproducing those diagnostic of this disorder. Initially 
it was thought that the injected material contained some sarcoid 
specific factor, such as an infectious agent or antigen236 but it has 
been recognised more recently that it relates to an abnormal host 
response:
“The “immune paradox” (delayed type hypersensitivity anergy 
in a setting of exuberant systemic granulomatous response) 
resists explanation. Its relationship to the Kveim test is poorly 
understood. Immunological investigations generated the thesis that 
the characterizing systemic granuloma arise as a fall-back reac-
tion to inefficient cellular immune processing, due most often to 
impaired myeloid dendritic cell function of unknown cause”237.
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Figure 7. Neutrophil accumulation and subsequent clearance of E. coli from the tissues is markedly delayed in a dose-dependent 
manner in CD. Reproduced from 219 with permission from the publisher. 111Indium-labeled autologous neutrophils were injected intravenously 
at the same time as killed E. coli were injected subcutaneously into each forearm. (a) Radioactivity measured over the injection sites showed a 
much smaller proportion of labelled cells accumulating in CD subjects. (b) γ-Camera image of a CD patient at 24 h after injection, demonstrating 
focal accumulations of radioactivity at bacterial injection sites (arrows) and confirming lack of bowel inflammation. (c) 32P-labeled killed 
E. coli were injected into the subcutaneous tissues of the forearm and radioactivity was measured at the skin surface. Clearance of 
radioactivity was much slower in CD than in HC or UC. Extrapolating these curves indicated that almost complete removal (99%) would 
take 10.2 and 7.1 d in HC and UC subjects, respectively, compared with 44.3 d in CD. (d and e) Effect of increasing bacterial dose from 
105 to 108 on blood flow (d) and bacterial clearance (e). The numbers of subjects studied in the dose response experiment are depicted 
in e. All results are expressed as mean ± SEM (**, P < 0.01; ***, P < 0.001).
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This is precisely the nature of the pathogenic mechanism in CD 
and it is therefore not surprising that positive tests are found in both 
conditions238 and that both diseases occasionally coexist in the same 
individual239.
On the location of the CD lesions
Symptomatic lesions are largely confined to the terminal ileum, 
caecum and colon, probably due to the combination of mucosal 
damage by enteric infection coupled with the ready presence 
of massive numbers of bacteria to penetrate into the wall of the 
bowel when this happens. However, it is becoming apparent that 
the gastrointestinal tract is generally diffusely, sub-clinically, 
abnormal.
Oral manifestation of CD, particularly aphthous ulcers, are estimated 
to occur in 20–50% of patients240. A prospective endoscopic study 
identified upper gastrointestinal (GI) manifestations of CD in 55% 
of 108 untreated, newly diagnosed adult patients with CD, irrespec-
tive of symptoms. All selected were free of H. pylori, infection with 
which, if anything, appears to protect against CD241. About a quarter 
of the patients had lesions in both the stomach and duodenum and 
in about 20% they were in one or other of these organs. In roughly 
2% of patients the gastric outlet is obstructed by a granulomatous 
inflammation requiring surgical intervention242. Aphthous ulcers in 
the oesophagus were present in 7% of these subjects. Most of these 
lesions exhibited a granulomatous inflammation on histology.
In view of the systemic nature of the impairment of the innate 
immune system in CD, it is of great interest, although not altogether 
surprising that patients with CGD54 exhibit very similar upper GI 
pathology. Aphthous ulceration and other oral lesions are common. 
Oesophageal, gastric and duodenal inflammation were detected 
in 21%, 74% and 37% of 78 patients53. Large bowel lesions were 
present in the majority53 and are indistinguishable from those of 
CD48,243. Between 4%244 and 15%245 of these patients also develop 
gastric outflow obstruction.
CGD is a condition in which there is a failure of microbial killing 
and digestion by neutrophils as a result of an absence of the respira-
tory burst produced by a NADPH oxidase, NOX2. Consequence, 
the pH of the phagocytic vacuole is too low for the efficient activity 
of the neutral protease digestive enzymes released into the vacuole 
from the cytoplasmic granules, and they fail to kill and digest the 
microbes246,247. The undigested material retained within the tissue is 
taken up by macrophages, producing the granulomata that give this 
condition its name.
Neutrophils play an important role in the debridement of 
wounds248,249, an important prelude and necessity for healing. It is 
possible that the upper GI inflammation that occurs in CD and CGD 
results from an impaired repair response to trauma and peptic diges-
tion rather than infection in these locations.
Identifying the molecular cause/s of the CD phenotype
The abnormality of innate immunity in most cases of CD 
lies in the macrophages
Defective secretion of pro-inflammatory cytokines in CD may 
be the explanation for the observed impairment in neutrophil 
recruitment219,250–253. In CD, the neutrophils themselves are 
normal254 and exhibit normal migration in vitro215,255,256 and will 
migrate out of skin windows if chemoattractant substances are 
placed over them216. In the absence of a primary abnormality of 
neutrophil function, CD macrophages showed defective secretion 
of pro-inflammatory cytokines, but normal release of chemokines, 
in response to stimulation with E.coli219 (Figure 8). The genes for 
these pro-inflammatory cytokines were transcribed and translated, 
but the proteins were misdirected to lysosomal degradation rather 
than secretion, suggestive of disordered vesicle trafficking.
The question then arises as to how anti-TNF drugs can be effective 
against a condition in which the secretion of TNF and other pro-
inflammatory cytokines is impaired? The answer is in the timing of 
the different components of the immune system. The call to arms 
of the innate immune system is a very early and explosive secretion 
of pro-inflammatory mediators, including TNF. If the clearance of 
faecal material from the tissues is incomplete, it becomes walled off 
by macrophages, endotoxin diffuses into the circulation, and cells 
of the adaptive immune system are recruited257. They secrete a wide 
array of mediators over the next weeks including TNF which acts as 
an amplifier of the response258. It is of interest that in a recent study 
of high-resolution gene expression profiling using RNA sequenc-
ing of inflamed biopsies from patients with CD, UC and controls, 
levels of pro-inflammatory cytokines like TNF, IL-1β, IL-6 and IL-23 
were all elevated to a lesser extent in CD than in UC259. The very 
early secretion of TNF and other mediators is required to prevent the 
development of the Crohn’s lesions whereas at a later stage it is the 
TNF and associated mediators that produce the symptoms, which 
in some cases respond to anti-TNF treatment. This explains why 
anti-TNF therapeutics can both cause260 and alleviate symptoms of 
the disease261.
What is the molecular cause of the impairment of acute 
inflammation?
There is a strong genetic component to the aetiology of CD. The 
sibling recurrence risk (risk of developing the disease in the con-
text of an affected sibling) is approximately 13–36262 and approxi-
mately 12%263 of CD patients have at least one affected first degree 
relative. Furthermore, the study of over 300 twin pairs has demon-
strated a higher concordance of disease phenotype in monozygotic 
(30%) compared with dizygotic twins (4%)264. While the twin stud-
ies support the role of genetic susceptibility, they also indicate the 
requirement for additional environmental or other factors for the 
development of overt disease. By far the most likely such factor is 
an enteric infection of sufficient severity to overwhelm the ability 
of the innate immune system to adequately clear the faecal debris 
from the bowel wall. However, this risk may be further modulated 
by additional environmental factors, such as smoking. This phe-
nomenon, whereby a genetic predisposition to disease manifests 
in the presence of environmental precipitants is exemplified by 
alpha-1-antitrypsin deficiency, in which the predisposition to 
emphysema is exposed by smoking265.
Technological advances have provided the means of interrogating 
the genetic basis of CD.
1. Linkage and Genome Wide Association studies (GWAS)
Linkage. Linkage analysis (positional cloning) is a family based 
technique for identifying the possible location within the genome 
of causal mutations underlying genetic diseases266. This is done 
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by utilising markers of known location across the genome, such 
as microsatellites or single nucleotide polymorphisms (SNPs). 
The transmission of the markers through a family (or collection of 
families) is examined seeking those whose segregation closely fol-
lows the inheritance of the disease, thereby focussing attention on a 
small region (locus) in which the causal mutation might be found266. 
Linkage analysis of affected sibling pairs with CD permitted the 
identification of a susceptibility locus on chromosome 16 (termed 
IBD1) in which mutations in the gene NOD2 were subsequently 
identified267,268. NOD2 mutations remain the most strongly associ-
ated common genetic variants associated with CD. Linkage is only 
a powerful tool when almost all cases of the disease in the families 
under study are caused by mutations in the same gene (i.e. there is 
limited genetic heterogeneity) that are not seen in unaffected family 
members (i.e. it is of high penetrance). Numerous factors can limit 
the effectiveness of linkage analysis such as: the presence of unaf-
fected individuals that harbour the mutation (incomplete penetrance); 
individuals who develop the disease as a result of mutations in 
another gene or due to environmental factors (phenocopies); the 
requirement for the combined effect of two or more mutations 
(epistasis); or the requirement of the involvement of some envi-
ronmental factor such as an infectious trigger (which will effec-
tively reduce penetrance by not facilitating the manifestation of the 
underlying genetic predisposition in unexposed individuals). All of 
these factors are likely to have contributed to the limited success of 
linkage analysis in CD.
GWAS. Genes reside on chromosomes which undergo recom-
bination at meioses. Population level haplotypes arise due to the 
non-random positioning of crossing-over events. Haplotypes are 
characterised by a particular set of SNP genotypes. Depending 
on the ancestral origin and frequency with which a mutation has 
arisen in the population, it may occur on a particular haplotype and 
thus the SNP genotypes defining that haplotype will be enriched in 
patients harbouring the disease-causing mutation. Therefore, when 
comparing a large population of diseased individuals with healthy 
controls, SNPs tagging the underlying mutation should be enriched 
in the affected compared with unaffected individuals. In GWAS, 
a set of SNPs are genotyped in an attempt to cover the whole-
genome and the above comparison made269. One of the major prob-
lems with analysing many hundreds of thousands (or millions) of 
markers across the genome is that the large number of comparisons 
undertaken risks producing false positives. This necessitates the 
utilisation of a stringent p-value threshold for significance of 
p<5×10-8270. As a result very large sample sizes are required271,272.
One of the technical strengths of GWAS as an investigative approach 
is that DNA is easily obtained and once purified it is stable, ena-
bling it to be conveniently stored and transported. Technological 
advancements have permitted high throughput SNP genotyping of 
large numbers of samples on an industrial scale. Furthermore, the 
GWAS approach has the advantage of being comprehensive (com-
pared with candidate gene studies) and objective (at least up until 
the stage of data interpretation). There are however a number of 
limitations, for example incomplete genomic coverage. In addi-
tion, a major drawback is that the SNPs employed as markers must 
be relatively common in the general population, in order to give 
the study adequate statistical power, so this approach is typically 
unable to identify low frequency mutations, however penetrant or 
important.
When a SNP is found to be statistically significantly associated with 
a disease by GWAS, it can be because the polymorphism is itself 
pathogenic or, more commonly that it is tagging a closely located 
genetic variant whose genotype correlates with that of the tagging 
polymorphism (the two variants are in linkage disequilibrium). The 
precise location of the causal variant(s) underlying the association 
signal within the identified locus may be interrogated further by 
fine mapping (in which higher resolution association studies are 
conducted) or by resequencing the locus looking for plausible 
Figure 8. Proinflammatory cytokine secretion by macrophages from CD patients is deficient in response to E. coli. Cytokine and 
chemokine release expressed as a percentage of that secreted by HC cells (blue bar) from ileal and colonic CD patients (reproduced from 
219 with permission from the publisher).
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pathogenic variants such as coding variants or those that affect 
gene-expression (eQTLs).
Increasingly large GWAS have been performed on CD and the results 
meta-analysed273,274. No single, or small number, of penetrant muta-
tions have been found that independently cause the disease. The 
latest study of over 20,500 CD cases and 41,600 controls of 
European ancestry identified 145 loci associated with CD at 
p<5×10-8. The mean OR of the top SNPs representing these 145 
loci was 1.16 and the mean control allele frequency was 0.48. 
Four SNPs had an OR exceeding 1.5 of which three were within 
NOD2 and the fourth was in IL23R. The mean difference in allele 
frequency between cases and controls was only 0.02275.
The very significant p-values obtained for the associated loci, led 
to the general perception that the molecular causes of CD have 
been identified. Individually the CD GWAS loci have very modest 
effect sizes (i.e. a small difference in frequency in the control and 
CD populations), consistent with a polygenic model in which it is 
thought that that it is the combination of these minor influences that 
is causally important. However, in the latest meta-analysis, all 170 
significantly associated loci combined account for only 10.9% of 
the disease “heritability”273.
An important consideration is that about half of the healthy popu-
lation also carry these variants, although (by definition) each at a 
slightly lower frequency than in the CD patients (Figure 9). The 
healthy controls carrying these variants greatly outnumber the 
patients with CD in the population. With a prevalence of CD of 
about three patients in 1000277, and taking the NOD2 frameshift 
mutation as an example because it has the greatest effect size at 3.32, 
for every 100,000 individuals in the population there will be 99,680 
unaffected individuals of whom ∼2390 will carry this mutation. In 
this population there will be ∼320 CD cases of which ∼48 will have 
the mutation274. This means that the penetrance of this mutation, 
with by far the greatest association with the disease, is only 2%. 
These effect sizes pale into insignificance when compared with the 
effect size of HLA-B27 in ankylosing spondylitis of approximately 
94278,279, and HLA in type 1 diabetes and coeliac disease with effect 
sizes of approximately 25 and 50, respectively280.
GWAS conducted on Europeans and East Asian populations have 
yielded noticeably different findings (Figure 10)276. In East Asian 
populations, the loci with largest effect sizes were those harbour-
ing the genes TNFSF15/TNFSF8 (genes encoding cytokines that 
belong to the tumour necrosis factor (TNF) ligand family281) and the 
major histocompatibility complex. Variants in NOD2 and ATG16L1 
demonstrated no association with CD in these populations, and 
the effect size of the IL23R locus was minimal. The significant 
heterogeneity in common variant CD genetic architecture between 
different populations provides a further indication that the genes 
identified by GWAS are unlikely to play a primary causal role in the 
development of the disease, the manifestations of which are similar 
in patients regardless of their ethnicity.
GWAS have been performed for many different diseases and IBD 
associated loci have been shown to be shared with several other 
immunologically mediated diseases including rheumatoid arthri-
tis, systemic lupus erythematosus (SLE), ankylosing spondylitis, 
coeliac disease and sarcoidosis282. These associations are not 
surprising as comorbidities of some of these conditions are well 
recognised in the context of IBD283–285 and because almost all are 
associated with an increased incidence of similar pathologies such 
as arthritis286, uveitis287,288 and bowel inflammation289–292.
Many of the associated genes common to these conditions have 
been implicated in pathways leading to activation or regulation 
of the immune response282. It is possible that these genes were 
highlighted as being common to the chronic inflammatory con-
ditions because they lead to more florid manifestations, causing 
signs and symptoms of the disease in those individuals with an 
underlying predisposition, thereby bringing them to the attention of 
the medical profession.
Despite their unimpressive effect sizes, the main GWAS CD 
associated molecules have generated considerable attention and 
are hence worth of a brief summary.
NOD2. NOD (Nucleotide-binding Oligomerisation Domain) 2 
is a member of an extended family of inflammatory and immune 
proteins in plants (the resistance (R) genes293), Drosophila (Toll- 
like receptors294) and animals (NOD families). These proteins 
combine a central nucleotide-binding domain (NOD) with a 
C-terminal leucine-rich repeat (LRR) motif and an N-terminal 
caspase recruitment domain (CARD) or equivalent.
In general these proteins recognise a signal from an invading 
organism in their leucine-rich domain (LRR) domain that induces 
Figure 9. The allele frequency in Crohn’s disease patients and 
healthy controls for top 20 of 144 CD associated GWAS SNPs 
sorted by odds ratio. The data were taken from the European cohort 
in 276. Loci harbouring genes of interest have been indicated.
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a polymerisation that triggers a signalling cascade which termi-
nates in the production and release of pro-inflammatory molecules. 
NOD2 is activated by muramyl dipeptide (MDP) a component of 
the cell wall of both Gram negative and Gram positive bacteria. It 
seems to be taken into the cells within endocytic vacuoles; presum-
ably the organisms are then digested within this compartment and 
the solubilised MDP is moved into the cytoplasm by peptide trans-
porters like SLC15A3295. Very recently it has been demonstrated 
that NOD1 and NOD2, do not only respond to bacterial stimuli, 
but are also important mediators of ER-stress-induced inflamma-
tion (described in more detail below)296.
In the resting state NOD2 is doubled back on itself in an auto- 
inhibited conformation in the cytoplasm until activated 
by the attachment of MDP upon which opens it allowing 
self-oligomerisation and the binding of ATP297,298. A series of 
phosphorylation steps then end in the translocation of NF-ΚB to the 
nucleus and the production of pro-inflammatory cytokines and 
antimicrobial peptides297. This theoretical model of NOD2 func-
tion as a pattern recognition receptor capable of inducing pro- 
inflammatory cytokine secretion has been validated by in vivo 
studies in humans in which the application of MDP to skin windows 
induced the production and release of pro-inflammatory cytokines 
in healthy and CD patients without NOD2 mutations, but not in 
those carrying the CD-associated mutations216. The impaired secre-
tion of these inflammatory mediators into skin windows in the 
absence of MDP, in CD patients without mutations in NOD2 in 
this study, demonstrates that other pro-inflammatory signals and 
pathways must be abnormal in these subjects, indicating that there 
are at least two parallel routes initiating the inflammatory response.
Figure 10. Comparison of the variance explained per risk variant for Crohn’s disease between East Asians and Europeans. Each box 
represents an independently associated locus and the size of each box is proportional to the amount of variance in disease liability accounted 
for by that locus in the respective population. From 276 (reproduced with permission from the publisher).
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Expression of NOD2 is largely restricted to peripheral blood 
monocytes299 and to Paneth cells at the base of intestinal crypts300. 
Monocytes constitute approximately 5% of the circulating 
leukocytes and are generally regarded as functioning predomi-
nantly as circulating precursors of macrophages, without much 
in the way of a distinct set of functions of their own. It seems 
intuitively unlikely that a highly specialised cell with an active 
NADPH oxidase and granules containing myeloperoxidase, all of 
which are lost with the transformation to macrophages, would be 
produced to act predominantly as a stem cell.
It is generally assumed that pro-inflammatory cytokines are secreted 
by tissue macrophages, but these are quite widely dispersed 
amongst tissues and could not accumulate as rapidly as needed at 
inflammatory sites as monocytes that are carried there in capillaries 
perfusing the region301,302. Monocytes are rapidly recruited to sites 
of acute inflammation where they extravasate into the tissues303 
and make a large contribution to the production of pro- 
inflammatory cytokines304–306 before being transformed into 
inflammatory macrophages.
Autophagy and ATG16L1, CALCOCO2/NDP52, LRRK2 and 
Optineurin. First described in the new-born mouse kidney by Clark 
in 1957307 and reviewed by De Duve and Wattiaux308, autophagy 
was initially described as a process in the cytoplasm of cells 
directed to the remodelling of tissues and the removal or damaged 
or effete organelles and proteins, and to partial self-digestion under 
starvation conditions.
To undertake this process, cells must first identify the region of 
cytoplasm, effete organelles, or invading microbes, as objects for 
engulfment. This is achieved by labelling the surface of the target 
with chains of a small protein, ubiquitin309,310. The ubiquitinated 
material is then encircled by a double membranous structure, 
produced from elongated vesicles at the Golgi apparatus or (ER)311, 
the ends of which then fuse to form the characteristic vacuole with 
a double membrane. This autophagocytic vacuole then fuses with 
lysosomes containing enzymes that digest the inner membrane and 
its contents312.
Membrane vesicle extrusion, ubiquitination and fusion of granules 
with vesicles are general biological processes that are involved in 
many diverse cellular functions in addition to autophagy. Most of 
the cellular machinery required for these processes in autophagy 
was identified in mutant Saccharomyces cerevisiae313 and homo-
logues were then then found in Drosophila and man. The molecular 
basis of human autophagy has largely been investigated in pro-
myelocytic HL60 and the Human Embryonic Kidney (HEK293) 
cell lines314,315. Thus the autophagy molecules have been identi-
fied in assays that measure autophagy in primitive cells. This does 
not mean that these proteins are necessarily exerting their effects 
exclusively through autophagy in more mature cells and tissues.
What is probably of particular relevance to CD is the specialised 
type of autophagy, known as xenophagy, that is designed to deal 
with bacteria that escape into the host cytosol (such as Shigella 
or Listeria) or those that reside in a modified intracellular vacu-
ole (such as Salmonella and Mycobacteria), which is important 
for the entrapment and lysosome-mediated degradation of 
bacterial pathogens316–318. CD resulting from abnormal xenophagy 
is seen in Niemann-Pick disease type C1 and XIAP deficiency with 
NOD2 variants in Crohn’s disease319. Other proteins implicated in 
xenophagy are the autophagy receptor CALCOCO2/NDP52320, 
Leucine-rich repeat kinase 2 (LRRK2)321 and Optineurin322,323.
Despite the current interest in autophagy and in exploring the 
removal of intracytoplasmic organisms from intestinal cells and 
macrophages by xenophagy, it must not be forgotten that the vast 
majority of bacteria entering the body are phagocytosed, killed and 
digested by neutrophils, and that xenophagy only has to deal with a 
tiny minority escaping this process.
ATG (autophagy-related)16L1. Attention was focussed upon 
ATG16L1 when an association was demonstrated with CD in a 
GWAS study324. The SNP was a common, non-synonymous variant 
resulting in an amino acid change from threonine to alanine at 
position 300 of the full-length protein (T300A) with an odds ratio 
of only 1.26274. The ATG16L1 protein was shown to be mainly 
expressed in the thymus, prostate, liver, kidney and colon with little 
in the small bowel, and equal levels were found in the bowel from 
healthy and CD subjects with and without the polymorphism.
ATG16L1 is recruited to the ER at the initiation of the forma-
tion of the autophagosome at this site315. It is involved in bind-
ing to ubiquitinated cytosolic Salmonella whilst these are 
enveloped in the phagophore to form the autophagosome325 and 
could be important for the clearance of bacteria from within 
cells315,326–328. This protein could be related to CD through the 
impaired clearance of intracellular organisms. It has been reported 
that the cellular architecture of Paneth cells is grossly distorted 
in knock-out mice severely depleted in this protein329 and in CD 
patients homozygous for the T300A polymorphism. In the mice, 
there were many fewer granules in these cells, with their normal 
contents lying predominantly in the cytoplasm, together with mul-
tiple large vesicular structures that might represent the membranes 
that would normally surround granules. The rest of the bowel 
looked normal329. It was also reported that CD patients with the 
T300A polymorphism demonstrated similar morphological changes 
with disorganized, or diminished, granules or exhibiting diffuse 
cytoplasmic lysozyme staining. This was claimed to be the first 
indication that Atg16L1 has a specific role in humans and mice in 
regulating the specialized properties of Paneth cells, and provides 
a novel and relevant mouse model that emulates one of the many 
diverse pathological hallmarks of human CD. Unfortunately the 
morphology of Paneth cells was not examined in healthy humans 
with the same polymorphism, which would not have been difficult 
given that 27% of this population is homozygous for the “risk” 
allele and 50% heterozygous, and which makes a pathological role 
for this SNP highly improbable274.
It has been reported that the T300A significantly increases ATG16L1 
sensitisation to caspase-3-mediated processing330. Metabolic stress 
in human and murine macrophages increased degradation of the 
T300A (or mouse equivalent) variants of ATG16L1, respectively, 
resulting in diminished autophagy and knock-in mice harbouring 
the variant showed defective clearance of Yersinia enterocolitica 
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and an elevated inflammatory cytokine response. Deletion of the 
caspase-3-encoding gene or elimination of the caspase cleavage site 
by site-directed mutagenesis rescued starvation-induced autophagy 
and pathogen clearance.
IRGM. Immunity related p47 guanosine triphosphatases (GTPases) 
or IRGs are a group of 47–48 kDa proteins that are implicated in 
the eradication of organisms like mycobacteria that are taken into 
cells within phagocytic vacuoles. IRGM has been characterised as 
an autophagy related molecule331 on the basis that it was associ-
ated with vacuoles thought to contain mitochondria, a character-
istic in common with autophagocytic vacuole. The evidence for 
the mitochondrial contents was the accumulation in the vacuoles 
of Mitotracker Red, a dye that partitions in mitochondria by virtue 
of the charge across their membranes. Mitochondria are marked for 
degradation by ubiquitination when they have lost their membrane 
potential332 and this situation would not be improved by degrada-
tion within an autophagosome, so it is unlikely that such structures 
would attract Mitotracker Red. On the other hand, potentials are 
developed across the membrane of the phagocytic vacuole by the 
NADPH oxidase333 and by electrogenic proton pumping of the 
vacuolar V-ATPases334. The classification of IRGM as primarily 
involved in the autophagocytic processes on the evidence provided 
for mitophagy should be reconsidered.
The IRGs were discovered in mice as interferon-gamma inducible 
elements that were important for resistance to microbes engulfed into 
phagocytic vacuoles. There are 23 of these molecules in mice but 
only one or very few in humans335. In human cells IRGM is largely 
expressed in immune cells whereas in mice it is almost exclusively 
in macrophages in which its expression is massively increased 
by LPS (336GeneAtlas MOE430 gcrma, Probeset: 1418825_at). 
Phagosomal maturation337,338 occurs through sequential fusion of 
the phagosome with early endosomes and lysosomes, resulting in 
acidification of the phagosome, release of hydrolytic proteases and 
death and digestion of the phagosome-bound pathogen. IRGs are 
located in the ER or Golgi compartments and after the host cell is 
infected, they are transported to pathogen-containing phagosomes/
vacuoles, where they modulate the formation or processing of the 
phagosome, undermining pathogen survival either directly or by 
facilitating the action of intracellular effector molecules.
XBP1 (X-box binding protein 1) and ER stress, or unfolded 
protein response (UPR)339,340. The ER is the principal organelle 
involved in the synthesis, maturation, and post- or co-transla-
tional modification of secreted and membrane proteins, as well 
as in various metabolic processes including dynamic ion stor-
age and biogenesis of membrane structures341. Properly folded 
proteins are then directed to the Golgi apparatus, to other intracel-
lular organelles, and to the extracellular surface by the secretory 
pathway342. The ER stress or unfolded protein response develops 
when the protein synthetic process becomes disordered; lead-
ing to the accumulation of dysfunctional unfolded protein as a 
result of genetic or adverse environmental factors. To deal with 
this, the unfolded protein triggers the unfolded protein response 
(UPR)343 which includes reducing protein synthesis by downregu-
lating mRNA translation, synthesising more molecular chaper-
ones to assist protein folding, and degrading misfolded proteins 
which are ubiquinated and directed to the proteasomes. XBP1 is a 
transcription factor that plays a central role in activating these ER 
stress responses344, and unexpectedly, NOD1 and NOD2 have been 
shown to be important mediators of this process296. Abnormalities 
in the ER stress response will produce unfolded proteins that will 
require removal by autophagy, so the linkage between these two 
processes is to be expected345.
Major demands are made on the protein synthetic machinery 
in rapidly turning over cells like the intestinal mucosa, and 
this is particularly true of cells like Paneth and goblet cells that 
secrete proteins in addition to attending to their own homeostatic 
requirements. When additional requirements for protein synthesis 
are called upon, induced, for example, by infection or chemical 
toxins, defects in the ER stress response could weaken the mucosa 
leading to ulceration346.
LRRK2. A considerable amount of work has been done on this 
protein because mutations in LRRK2 cause familial and sporadic 
Parkinson’s disease (PD). It is a large, 280kDa, protein with 
GTPase and kinase domains, the latter being constitutively active 
in PD. It is found in immune cells, in lamina propria macrophages, 
B-lymphocytes and dendritic cells, and levels are markedly 
increased in the bowel in CD321 and in microglia in the nervous 
system347. It interacts with the small GTPases Rab32 and Rab38 
with which it co-locates to transport vesicles and recycling 
endosomes348 and it is important for the elimination or intracel-
lular Salmonellae349 and Legionella350. Rab32 and Rab38 play an 
important role in the biogenesis and traffic of melanosomes and 
lysosomes and this system is disordered in Hermansky-Pudlak 
syndrome351, accounting for the characteristic partial albinism. If 
LRRK2 and its associated proteins are important for immunologi-
cal resistance to the development of CD then it might be expected 
that CD would be more common in conditions in which the 
LRRK2 system is disordered, which is in fact the case. A 
clear association exists between CD and PD352,353 and CD and 
Hermansky-Pudlak354. At least two recent studies have discovered 
a link between mutations in LRRK2 and CD in Ashkenazi Jews 
(submitted for publication).
Summary of outcome of GWAS studies in CD
The GWAS studies have provided a series of clear answers. No 
single gene, or a small number of genes, has been identified that is 
causal for CD. More than 170 GWAS hits combined contribute to 
about 10% of the “heritability” of CD. With the average individ-
ual contribution of only 0.1% it is unlikely that these variants will 
individually have major effects on cellular function, either in the 
CD patients or in experimental systems.
One of the founding premises of GWAS was that it was designed 
to identify genes that are involved in pathways relevant to disease 
pathogenesis. The value of this data, therefore, is that it points 
towards the specific pathways that are likely to be involved in 
disease pathogenesis, rather than identifying causal genes. 
Collectively, genes associated with CD by GWAS are enriched 
for Gene Ontology (GO) annotations (statements describing the 
functions of specific genes) related to host-microbe interactions, 
the regulation of cytokine production, lymphocyte activation and 
the response to molecules of bacterial origin273. This is in keeping 
with the large body of data that is accumulating as to the role of 
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the innate immune system and its interaction with intestinal 
microbes in the causal mechanisms in CD.
Other investigations to identify causal molecules
Macrophage expression profiling
In the knowledge that the release of pro-inflammatory cytokines 
by macrophages from CD subjects is depressed as a result of 
impaired vesicle trafficking219, an attempt was made to identify 
genes contributing to this deficiency by looking for outlier levels 
of gene expression in these cells. The most commonly under-
expressed gene identified was Optineurin, low expression levels of 
which were found in 10% of CD patients studied355. ADAMDEC1 
was under-expressed in about 7% of patients.
Optineurin (Optn)322,323 is a 67 kDa protein, ubiquitously expressed, 
and its expression can be induced by TNFα and interferons, prob-
ably as a result of NFκB activation, and it is localised in the cytosol 
and Golgi apparatus. In essence it is a linker, or adaptor, molecule 
and has several binding partners including Rab8, Huntingtin, the 
gene for which is mutated in Huntington disease, and Myosin VI, 
a multifunctional motor protein. Rab8 is a small GTPase involved 
in vesicular trafficking between the trans-Golgi network (TGN) 
and the plasma membrane. The function of Huntingtin itself is 
unknown but it is associated with several factors involved in vesicle 
trafficking. Myosin VI is attached by OPTN to the Golgi apparatus 
and then it participates in the transport of vesicles and their protein 
cargos from the from the Trans-Golgi network to be released at the 
cell surface. OPTN also contains a ubiquitin binding domain with 
the ability to bind polyubiquitinated cargoes and transport them 
to autophagosomes via its microtubule-associated protein 1 light 
chain 3-interacting domain356.
Macrophages from patients with low expression of OPTN secreted 
abnormally low levels of pro-inflammatory cytokines as do mac-
rophages from OPTN knock out mice357. mRNA expression levels 
of these cytokines were normal, consistent with deranged secretion 
rather than synthesis. These mice were more susceptible to infection 
with Citrobacter, E. coli and Salmonella358, and showed reduced 
levels of TNFα in their serum, diminished neutrophil recruitment 
to sites of acute inflammation and greater mortality, than wild-type 
mice. OPTN-knockdown zebrafish infected with Salmonella also 
had a higher mortality357.
ADAMDEC1 (ADAM-like Decysin-1) is a member of the ADAM 
(A Disintegrin And Metalloproteinase) family, the expression of 
which is restricted to the macrophage/dendritic cell populations 
of the gastrointestinal tract. Its biological function is unknown 
but it has been hypothesised to play a role in immunity. Reduced 
ADAMDEC1 expression in macrophages from a subgroup of 
CD patients has provided evidence of a potential role in bowel 
inflammation355. Adamdec1-/- mice were more susceptible to the 
induction of bacterial and chemical induced colitis and they cleared 
Citrobacter rodentium less efficiently than wild-type mice after 
infection359.
DNA sequencing
The development, availability and falling costs of high throughput 
DNA sequencing, has provided the means of directly identifying 
causal mutations in human disease360,361. Several studies employing 
such technology have been undertaken in CD362,363 and many more 
are likely to appear over the ensuing years. High-throughput DNA 
sequencing has also been absolutely crucial for the diagnosis of the 
rare primary immunodeficiencies47 that produce bowel inflamma-
tion, rather than CD, as described earlier.
Initially the DNA of GWAS associated loci was sequenced, and a 
small number of rare variants were identified, most notably in the 
genes CARD9 and IL23R364,365.
The major problem in identifying causal genes by sequencing is  the 
considerable individual variation in DNA sequence. Asymptomatic 
individuals carry, on average, approximately 100 genuine loss of 
function variants with ∼20 genes completely inactivated366. This 
makes it very difficult to identify the disease causing mutation/s in 
any one individual.
Of note, an ongoing study in which whole-genome sequencing 
has been undertaken in 2,697 CD cases and 3,652 healthy controls 
failed to identify a single variant at genome-wide significance that 
had not already been identified by GWAS367.
Alternative approaches have been taken to overcome the difficulty 
of the interpretation of individual variation. Several studies have 
focussed on the analysis of Ashkenazi Jews (AJ) because they 
have a roughly fourfold increased incidence of CD and demon-
strate genetic homogeneity, having arisen from approximately 350 
individuals about 30 generations ago368.
Chuang et al. sequenced the exomes of 50 AJ CD patients and pri-
oritised low frequency coding variants which were then genotyped 
in approximately 3,000 AJ CD cases and 3,000 controls. They identi-
fied a frameshift mutation in CSF2RB as a strong causal candidate 
which was associated with CD at p<3.5×10-6 and an OR of 1.5369. 
This variant is rare in the non-AJ population.
Levine et al. utilised an alternative family based approach370. They 
characterised two very large AJ families with >800 and >200 
members with 54 and 26 affected cases respectively, sequenced 
the exomes of all cases and imputed the genotypes of the unaf-
fected family members. Low frequency coding variants that were 
predicted to be damaging and were enriched in affected compared 
with unaffected individuals were prioritised. In the large family 
they independently identified the identical frameshift mutation 
in CSF2RB as concurrently reported by Chuang et al. as a likely 
causal variant. Other strong candidate genes included NLRP2, a 
NOD-like receptor and a component of the inflammasome; ZC3H18 
which is involved in IKK and NFκB activation371, a pathway of 
established importance in CD; and MEGF10, a phagocytic receptor 
involved in apoptosis372.
CSF2RB
Having been identified independently by two groups CSF2RB 
must be considered as a causal gene for CD in AJs373. CSF2RB 
is the common or shared β subunit of the receptors for granulo-
cyte-macrophage colony-stimulating factor (GM-CSF), interleukin 
(IL)-3, and IL-5374. The distinct α chains of these receptors pro-
vide cytokine specificity whilst the β chain is responsible for high- 
affinity binding and is the major downstream signalling component 
of the receptor complexes.
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GM-CSF is produced by myeloid cells, dendritic cells (DCs), 
T cells, B cells, and several non-immunological cells including 
epithelial cells375 following exposure to inflammatory stimuli to 
promote the production and function of myeloid haemopoietic cells 
including haemopoietic progenitor cells and differentiated cells such 
as basophils, neutrophils, eosinophils, macrophages and certain 
dendritic cells376 to deal with the cause of the inflammation.
IL-3 is predominantly produced by activated T cells, natural killer 
(NK) cells and mast cells. It acts on the early stages of haemat-
opoiesis in synergy with other cytokines to induce progenitors of 
various lineages but it is a very important stimulus for the genera-
tion of mast cells and the regulation of mast cell function as well as 
basophil production and activation.
IL-5 stimulates mainly the production and function of eosinophils. 
The major source of IL-5 is T-cells with relatively lower amounts 
produced by mast cells and eosinophils377.
DUOX2
Levine et al. also identified a damaging missense mutation in 
DUOX2 that impaired the function of the protein and showed a 
possible epistatic interaction with NOD2370. DUOX2 is a mem-
ber of the large NADPH oxidase (NOX) family of enzymes378. Its 
expression in the bowel epithelium is induced by the microbiota379. 
It generates H2O2 at the mucosal surface and this acts as substrate 
for lactoperoxidase catalysed oxidation of thiocyanate to micro-
bicidal hypothiocyanite6. It might also attract neutrophils to 
inflammatory sites380. Knockdown of the DUOX2 homologue 
in invertebrates and mice resulted in an impaired tolerance to 
enteric bacteria381. Of relevance, given the possible NOD2 epistatic 
interaction observed, a physical and functional interaction between 
these proteins has been demonstrated in epithelial and HEK293 
cells382.
Future treatment options
Treatment of CD poses a conundrum. The logical approach to 
correcting the underlying problem would be to develop means of 
enhancing innate immunity, although at present no such range of 
drugs is currently available. It would be dangerous to attempt to 
do this in the presence of ongoing bowel inflammation but it could 
be useful to maintain patients in remission after they had been 
cleared of disease by surgical resection, or through the use non-
immunosuppressant therapies such as elemental diets383. This 
approach was attempted with levamisole384 as the immunostimu-
lant, with varying results385,386. One problem with this form of 
treatment is that it is important to ensure that the patients are in 
remission before it is commenced; otherwise it is likely to exacer-
bate the inflammation. In two studies levamisole induced a severe 
reversible polyarthropathy387,388, indicating that the drug was in 
fact altering the immunological/inflammatory axis, and providing 
clues as to IBD associated arthritis, and to the immunopathology of 
the idiopathic arthritides in general.
Current drug and biological treatments are largely immunosup-
pressant. This, to varying degrees of efficiency, dampens down the 
secondary inflammation induced by the retained foreign material 
within the tissues. Anti-TNF treatments can be very helpful but do 
not provide a comprehensive answer. Only one third of patients 
will be in remission after one year on these treatments389. Immuno-
suppressant treatment further compromises the underlying innate 
immune deficit to mucosal damage, thereby increasing the like-
lihood of further infection and the influx of bowel contents into 
the tissues, possibly converting CD from a sporadic to a chronic 
condition.
The primary pathology in most case of CD appears to affect macro-
phages recruited from the blood as monocytes301. Advances in gene 
editing with the CRISPR-Cas390,391 technology make the correc-
tive treatment of CD a real possibility in the relatively near future. 
Once a primary causal mutation has been identified, and validated 
in animal models, bone marrow could be extracted, edited and rein-
fused into a conditioned patient in much the same way as is being 
applied to gene therapy for primary immunodeficiencies392.
Conclusion
After almost a century of concerted effort in clinical investigations 
combined with recent technological developments in genomic med-
icine, a consensus view is developing as to the causes of CD.
A genetic predisposition to the condition can exist, as evidenced 
by twin and family studies. Studies in patients have clearly dem-
onstrated that there is a defect in the acute inflammatory response 
resulting in an impaired recruitment of neutrophils to inflam-
matory sites and a consequent delay in the clearance of bacte-
ria from them. This results from an initial blunted response by 
monocytes and macrophages leading to deficient secretion of pro- 
inflammatory cytokines.
CD is a syndrome and the molecular basis of this deficiency will 
vary considerably. It might reflect the multifactorial extreme 
end of a normal distribution, or the critical loss of one or more 
important molecules. Molecules contributing to the former will 
be very difficult to identify whereas some of those playing a 
more singular role have been highlighted by linkage, GWAS and 
DNA sequencing studies. These extend across the spectrum of the 
interface between microbes and cells: from the derangement of 
cellular homeostasis, probably in intestinal and immune cells, 
through impairment of the ER stress response (XBP1 malfunc-
tion); defective signalling (aberrant NOD2); depressed killing and 
digestion of organisms within phagocytic vacuoles (IRGM) or 
xenophagic recovery of those that escape into the cytoplasm 
(ATG16L1); failure of vesicle trafficking resulting in disorgan-
ised lysosomal biology of reduced cytokine secretion (LRRK2, 
Optineurin) or ineffective signalling of cytokines on target 
cells because of aberrant receptors (CSF2RB). In addition, primary 
abnormalities of neutrophils, the final effector cells, constitute 
the ultimate predisposition.
However severe the covert underlying predisposition, it requires a 
triggering factor to be expressed, and all the evidence points to this 
being an enteric infection. The identity of the organism is of sec-
ondary importance to the fact that the mucosa is breached, allow-
ing ingress of the faecal contents into the bowel wall. Increased 
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frequency or potency of these infections, as a result of factors impli-
cated in the “Hygiene Hypothesis” or through increased spread 
by travel, or changes in sexual practises, could account for the 
increasing incidence of CD in the Western world.
It is the abnormal response to the penetrating faeces that is the com-
mon denominator of the CD syndrome, and it is the failure to elimi-
nate the foreign material in the tissues that leads to the classical 
chronic granulomatous inflammation, and subsequently to an adap-
tive immune response. The counter intuitive, but logical, conclusion 
is that a disease characterised by grossly exuberant inflammation 
can result from an initial failure of innate inflammation. A similar 
mechanism might be responsible for other chronic inflammatory 
conditions of unknown aetiology, like for example sarcoidosis, 
ankylosing spondylitis, psoriasis, rheumatoid arthritis and SLE.
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I think the revisions are helpful and agree that GWAS has not identified single genes that can cause
Crohn's disease. The revised text highlights both this point and that the value of GWAS lies in identifying
pathways that may be involved. So as not to dissuade investigators from studying the effects of
disease-associated genetic variants, however, I think it is important to note that a small odds ratio does
not mean that variants cannot have effects on cellular function (for reasons including functional
redundancy and overlap as stated in my first review). For example, several GWAS hits have been shown
to drive relevant  and  phenotypes, which - through their elucidation - have added to ourin vitro in vivo
understanding of disease:
Nonetheless, I am happy to approve this manuscript, which I believe presents a thorough overview of the
pathogenesis of Crohn's disease and is an important contribution to the literature.
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This review presents a thorough overview of the pathogenesis of Crohn's disease, drawing on a broad
range of evidence, from epidemiology to human immunology to genetics. It is impressive to have collated
such diverse topics into a single review, and therefore understandable that some areas are discussed in
more detail than others. Overall this is a valuable contribution to the literature.
Of note, some parts of this review read more like a perspective piece and draw conclusions that I suspect
are not widely held, although they are supported by the evidence presented. There is also a considerable
focus on the author's own work in several sections, although this is understandable and it is valuable to
have these experiments discussed in the context of the broader literature regarding Crohn's disease
pathogenesis. 
The author is fairly dismissive of the role of genetics, and more specifically of the significance of
disease-associated genetic variants, based on their small odds ratios and frequency within the healthy
population. While I understand this opinion, I think it is important to clarify a couple of these points for a
general audience. First, it is important to note that one of the founding premises of GWAS was that it was
designed to identify genes that are involved in pathways relevant to disease pathogenesis. It was not
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designed to identify genes that are involved in pathways relevant to disease pathogenesis. It was not
expected - based on the common disease-common variant hypothesis - that any of the SNPs or genes
would by themselves be causal. To take the example of impaired autophagy - something that has been
commonly reported in Crohn's patients -  there are several ways in which this might occur. For instance
some patients may carry NOD2 or IRGM or ATG16L1 mutations, while in others it may be due to
environmental factors such as smoking - see Monick . (2010). Based on the multi-hit model the authoret al
proposes, the key point is that "hits" are simultaneously required in several pathways in conjunction with
an environmental trigger in order for a disease to occur. Because the exact nature of each hit is likely to
vary between patients, it is not surprising that univariate genetic analysis identifies small odds ratios at
individual SNPs (many of which may have similar effects on a given pathway). Moreover, the size of these
effects may be different when gene-environment and epistatic interactions are taken into account. The
value of this data, therefore, is that it points towards the specific pathways that are likely to be involved in
disease pathogenesis, rather than identifying causal genes.
This is perhaps best illustrated in cardiovascular medicine, where genetic variants in the gene that
encodes HMG-CoA reductase have been significantly associated with LDL cholesterol levels, but the
odds ratios for these associations are very small (presumably because there are many other causes of
elevated cholesterol, Kathiresan  (2008)). Despite this, pharamcological targeting of this enzyme withet al.
statins represents the most effective treatment for hypercholersterolaemia. As such, a small odds ratio at
individual SNP should not be confused with the implicated gene or pathway not being biologically or
therapeutically important. 
Other points:
Discussion of the ATG16L1 variant would benefit from including the recent evidence linking the
variant to susceptibility to caspase-mediated degradation (Murthy (2014)).et al. 
 
It would be worth highlighting the cross-talk between ER stress and autophagy, particularly in the
context of Crohn's (Adolph 2013)). et al.(
 
p.2: IL-23 is thought to be more involved in the expansion and survival of Th17 than in transforming
naive T cells into Th17 cells
 
p.7 typo: Danziel should be Dalzeil
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I am most grateful to Dr Lee for taking the time and trouble to thoroughly review my manuscript and
for his comments.
I would like to address the issue of the relationship between GWAS and the identification of causal
genetic variants. It is simple to establish causality for dominant, highly penetrant genes like
polycystic renal disease, polyposis coli and Huntington’s disease. However it is more difficult when
penetrance is incomplete, when one is reliant upon the odds ratio of the frequency of the variants in
affected as compared with unaffected individuals. In general very high odds ratios would strongly
suggest causality. Genes with very high odds rations have been identified by GWAS. For example:
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https://www.ncbi.nlm.nih.gov/pubmed/24957906
 
However, the most important consideration is not whether or not the design of GWAS was to
identify causal genes, but what the common perception is, and in many cases it is the perception
that GWAS do in fact generally identify causal genes:
The genetic background of Inflammatory Bowel Disease: From correlation to causality.
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It was therefore very important to state in the review that GWAS have not identified genes that
cause Crohn's disease. 
Under the I have now stated:Summary of outcome of GWAS studies in CD 
The GWAS studies have provided a series of clear answers. No single gene, or a small number of
genes, has been identified that is causal for CD. More than 170 GWAS hits combined contribute to
about 10% of the “heritability” of CD. With the average individual contribution of only 0.1% it is
unlikely that these variants will individually have major effects on cellular function, either in the CD
patients or in experimental systems.
One of the founding premises of GWAS was that it was designed to identify genes that are
involved in pathways relevant to disease pathogenesis. The value of this data, therefore, is that it
points towards the specific pathways that are likely to be involved in disease pathogenesis, rather
than identifying causal genes. 
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This is a very comprehensive review of the pathogenesis of Crohn's disease (CD). The paper thoroughly
covers all relevant aspects, including epidemiology, microbiology, immunology, and genetics. In that
regard, it is both holistic and reductionist -- a very rare combination nowadays. It is beautifully written and
presents a fair account of the current state of knowledge. Importantly, it is not biased: it does not resemble
any of the too many reviews on CD that provide more beliefs and opinions than facts. This is in my view
the very best review ever written on CD. This is clearly a must-read for anyone interested in this condition.
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